International Journal of Infection

Published by: Kowsar

Crimean-Congo Hemorrhagic Fever-Treatment and Preventive Strategies

Maryam Keshtkar Jahromi 1 , *
Author Information
1 Department of Infectious Diseases, Pennsylvania State University, Hershey, PA, USA
Article information
  • International Journal of Infection: July 30, 2014, 1 (2); e20310
  • Published Online: July 20, 2014
  • Article Type: Review Article
  • Received: January 19, 2014
  • Revised: February 27, 2014
  • Accepted: April 22, 2014
  • DOI: 10.17795/iji-20310

To Cite: Jahromi M K. Crimean-Congo Hemorrhagic Fever-Treatment and Preventive Strategies, Int J Infect. 2014 ; 1(2):e20310. doi: 10.17795/iji-20310.

Abstract
Copyright © 2014, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Prevention of CCHF
3. Treatment
4. Summary
References
  • 1. Prophylactic characteristics of a protective Crimean hemorrhagic fever vaccine, in: Chumakov. Crimean hemorrhagic fever Materials of the 3rd scientific-practical conference. : 136-8
  • 2. Christova I, Kovacheva T, Georgieva D, Ivanova S, Argirov D. Congo-Crimean haemorrhagic fever virus - Bulgarian input in fighting the disease. Probl. Infect. Paras. Dis. 2009; 37: 7-8
  • 3. Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, SchmalJohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine. 2006; 24(21): 4657-66[DOI][PubMed]
  • 4. Fisher-Hoch SP, Rehman S, Khan JA, Mirza S, Khurshid M, McCormick JB. Crimean Congo-Haemorrhagic Fever treated with oral ribavirin. Lancet. 1995; 346(8973): 472-5[DOI]
  • 5. Athar MN, Baqai HZ, Ahmad M, Khalid MA, Bashir N, Ahmad AM, et al. Short report: Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002. Am J Trop Med Hyg. 2003; 69(3): 284-7[PubMed]
  • 6. Bangash SA, Khan EA. Treatment and prophylaxis with ribavirin for Crimean-Congo Hemorrhagic Fever--is it effective? J Pak Med Assoc. 2003; 53(1): 39-41[PubMed]
  • 7. van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S Afr Med J. 1985; 68(10): 729-32[PubMed]
  • 8. Smego RJ, Sarwari AR, Siddiqui AR. Crimean-Congo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin Infect Dis. 2004; 38(12): 1731-5[DOI][PubMed]
  • 9. Jabbari A, Besharat S, Abbasi A, Moradi A, Kalavi K. Crimean-Congo hemorrhagic fever: case series from a medical center in Golestan province, Northeast of Iran (2004). Indian J Med Sci. 2006; 60(8): 327-9[PubMed]
  • 10. Midilli K, Gargili A, Ergonul O, Sengoz G, Ozturk R, Bakar M, et al. Imported Crimean-Congo hemorrhagic fever cases in Istanbul. BMC Infect Dis. 2007; 7: 54[DOI][PubMed]
  • 11. Alavi-Naini R, Moghtaderi A, Koohpayeh HR, Sharifi-Mood B, Naderi M, Metanat M, et al. Crimean-Congo hemorrhagic fever in Southeast of Iran. J Infect. 2006; 52(5): 378-82[DOI][PubMed]
  • 12. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran. Clin Infect Dis. 2003; 36(12): 1613-8[DOI][PubMed]
  • 13. Ozkurt Z, Kiki I, Erol S, Erdem F, Yilmaz N, Parlak M, et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect. 2006; 52(3): 207-15[DOI][PubMed]
  • 14. Elaldi N, Bodur H, Ascioglu S, Celikbas A, Ozkurt Z, Vahaboglu H, et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect. 2009; 58(3): 238-44[DOI][PubMed]
  • 15. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis. 2004; 39(2): 284-7[DOI][PubMed]
  • 16. Cevik MA, Elaldi N, Akinci E, Onguru P, Erbay A, Buzgan T, et al. A preliminary study to evaluate the effect of intravenous ribavirin treatment on survival rates in Crimean-Congo hemorrhagic fever. J Infect. 2008; 57(4): 350-1[DOI][PubMed]
  • 17. Tasdelen Fisgin N, Ergonul O, Doganci L, Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis. 2009; 28(8): 929-33[DOI][PubMed]
  • 18. Metanat M, Sharifi-Mood B, Salehi M, Alavi-Naini R. Clinical Outcomes in Crimean-Congo Hemorrhagic Fever: A Five-years Experience in the Treatment of Patients in Oral Ribavirin. Int J Virol. 2006; 2(1): 21-4[DOI]
  • 19. Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: a case-control study. Jpn J Infect Dis. 2009; 62(1): 11-5[PubMed]
  • 20. Sharifi-Mood B, Metanat M, Ghorbani-Vaghei A, Fayyaz-Jahani F, Akrami E. The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study. Arch Iran Med. 2009; 12(2): 151-3[PubMed]
  • 21. Koksal I, Yilmaz G, Aksoy F, Aydin H, Yavuz I, Iskender S, et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol. 2010; 47(1): 65-8[DOI][PubMed]
  • 22. Keshtkar-Jahromi M, Kuhn JH, Christova I, Bradfute SB, Jahrling PB, Bavari S. Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res. 2011; 90(2): 85-92[DOI][PubMed]
  • 23. Salehi H, Salehi M, Adibi N, Salehi M. Comparative study between Ribavirin and Ribavirin plus Intravenous Immunoglobulin against Crimean Congo hemorrhagic fever. J Res Med Sci. 2013; 18(6): 497-500[PubMed]
  • 24. Blackburn NK, Besselaar TG, Shepherd AJ, Swanepoel R. Preparation and use of monoclonal antibodies for identifying Crimean-Congo hemorrhagic fever virus. Am J Trop Med Hyg. 1987; 37(2): 392-7[PubMed]
  • 25. Lazarev VN. Arboviruses (Tick-borne and Japanese encephalitides, hemorrhagic fevers, and other arboviral infections). 1969; 2: 142-3
  • 26. Bertolotti-Ciarlet A, Smith J, Strecker K, Paragas J, Altamura LA, McFalls JM, et al. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J Virol. 2005; 79(10): 6152-61[DOI][PubMed]
  • 27. Erduran E, Bahadir A, Palanci N, Gedik Y. The treatment of crimean-congo hemorrhagic fever with high-dose methylprednisolone, intravenous immunoglobulin, and fresh frozen plasma. J Pediatr Hematol Oncol. 2013; 35(1)-24[DOI][PubMed]
  • 28. Sharifi-Mood B, Alavi-Naini R, Metanat M, Mohammadi M, Shakeri A, Amjadi A. Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia. Trop Doct. 2013; 43(2): 49-53[DOI][PubMed]
  • 29. Dilber E, Cakir M, Erduran E, Koksal I, Bahat E, Mutlu M, et al. High-dose methylprednisolone in children with Crimean-Congo haemorrhagic fever. Trop Doct. 2010; 40(1): 27-30[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments